A Randomized Comparison of Clinical Outcomes Between Everolimus-eluting Bioresorbable Vascular Scaffold Versus Everolimus-eluting Metallic Stent in Long Coronary Lesions

Inclusion Criteria: * Age 19-85 years * Patients with ischemic heart disease requiring PCI * Significant coronary de novo lesion (stenosis \>50% by quantitative angiographic analysis) requiring stent ≥28 mm in length based on angiographic estimation * Reference vessel diameter of 2.5 to 3.75 mm by operator assessment Exclusion Criteria: * Acute myocardial infarction within 48 hours with unstable hemodynamics requiring pharmacologic or mechanical support * Complex coronary morphology including left main disease and bifurcation lesion requiring two-stent technique * Contraindication or hypersensitivity to anti-platelet agents or contrast media * Treated with any metallic stent or BVS within 3 months at other vessel * Cardiogenic shock * Left ventricular ejection fraction \<40% * Pregnant women or women with potential childbearing * Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator * Inability to understand or read the informed content